Shaily Engineering Plastics Limited has informed the Exchange about Transcript

Shaily Engineering Plastics reported strong Q4 FY26 results with revenue of INR237 crores (up 9% YoY), EBITDA of INR69 crores (up 27% YoY), and PAT of INR40 crores (up 40% YoY). For FY26, revenue grew 26% to INR991 crores while PAT surged 83% to INR170 crores, with EBITDA margins expanding 630 bps to 29%. The healthcare segment was the standout performer, doubling in Q4 and growing 139% for the full year to INR393 crores, now contributing 40% of consolidated revenue. Key milestones include commercial launch of Semaglutide pen injectors in Canada and tentative U.S. approval. The company also entered new verticals with consumer electronics supplies commencing and a semiconductor tray supply agreement signed with a Korean company. The Board approved an enabling resolution to raise up to INR500 crores for future capital flexibility.